Christopher Ryan Sullivan - 26 Feb 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role: Chief Financial Officer
Signature: /s/ Christopher Sullivan
Issuer symbol: AVTX
Transactions as of: 26 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2026, 16:22:04 UTC
Previous filing: 12 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Sullivan Christopher Ryan	Chief Financial Officer	C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE	/s/ Christopher Sullivan	02 Mar 2026	0001810417

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVTX	Stock Option (Right to Buy)	Award	$0	+105,000		$0.000000	105,000	26 Feb 2026	Common Stock	105,000	$17.64	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.